1. The drug development pipeline for glioblastoma-A cross sectional assessment of the FDA Orphan Drug Product designation database
- Author
-
Markus Ries, Pascal Johann, and Dominic Lenz
- Subjects
0301 basic medicine ,Orphan Drug Production ,Databases, Pharmaceutical ,medicine.medical_treatment ,Malignant brain tumor ,Cancer Treatment ,Disease ,computer.software_genre ,Pediatrics ,0302 clinical medicine ,Cancer immunotherapy ,Medicine and Health Sciences ,Medicine ,Neurological Tumors ,Multidisciplinary ,Database ,Pharmaceutics ,Drug development ,Oncology ,Neurology ,030220 oncology & carcinogenesis ,Fatal disease ,Immunotherapy ,Research Article ,Drug Research and Development ,Drug Administration ,Blastoma ,Science ,Immunology ,Cancer Immunotherapy ,Pharmacological treatment ,Food and drug administration ,Orphan drug ,03 medical and health sciences ,Drug Therapy ,ddc:610 ,Pharmacology ,business.industry ,United States Food and Drug Administration ,Cancers and Neoplasms ,Biology and Life Sciences ,medicine.disease ,United States ,030104 developmental biology ,Cross-Sectional Studies ,Pediatric Oncology ,Clinical Immunology ,Clinical Medicine ,business ,Glioblastoma ,computer ,Glioblastoma Multiforme - Abstract
BackgroundGlioblastoma multiforme (GBM) is the most common malignant brain tumor among adult patients and represents an almost universally fatal disease. Novel therapies for GBM are being developed under the orphan drug legislation and the knowledge on the molecular makeup of this disease has been increasing rapidly. However, the clinical outcomes in GBM patients with currently available therapies are still dismal. An insight into the current drug development pipeline for GBM is therefore of particular interest.ObjectivesTo provide a quantitative clinical-regulatory insight into the status of FDA orphan drug designations for compounds intended to treat GBM.MethodsQuantitative cross-sectional analysis of the U.S. Food and Drug Administration Orphan Drug Product database between 1983 and 2020. STROBE criteria were respected.ResultsFour orphan drugs out of 161 (2,4%) orphan drug designations were approved for the treatment for GBM by the FDA between 1983 and 2020. Fourteen orphan drug designations were subsequently withdrawn for unknown reasons. The number of orphan drug designations per year shows a growing trend. In the last decade, the therapeutic mechanism of action of designated compounds intended to treat glioblastoma shifted from cytotoxic drugs (median year of designation 2008) to immunotherapeutic approaches and small molecules (median year of designation 2014 and 2015 respectively) suggesting an increased focus on precision in the therapeutic mechanism of action for compounds the development pipeline.ConclusionDespite the fact that current pharmacological treatment options in GBM are sparse, the drug development pipeline is steadily growing. In particular, the surge of designated immunotherapies detected in the last years raises the hope that elaborate combination possibilities between classical therapeutic backbones (radiotherapy) and novel, currently experimental therapeutics may help to provide better therapies for this deadly disease in the future.Article summaryStrengths and limitationsThis study provides a quantitative overview on the drug development pipeline for pediatric and adult oncology in general and specifically for the indication glioblastomaAnalyzing the therapeutic mechanisms of designated compounds in glioblastoma reveals an increased focus on personalized and targeted therapiesThe precise reasons for failure of approved drugs and for withdrawal of approved drugs in glioblastoms are unknownFor the analysis, only the databases “FDALabel” (https://nctr-crs.fda.gov/fdalabel/ui/search) and the FDA Orphan drug product designation database (https://www.accessdata.fda.gov/scripts/opdlisting/oopd/) were considered
- Published
- 2021